Platelet-rich plasma affects bacterial growth in vitro

Area of Science:

• Biomedical Engineering
• Microbiology
• Immunology

Background:

• Platelet-rich plasma (PRP) is a blood derivative gaining traction in tissue regeneration and engineering.
• Its high platelet concentration suggests potential roles in tissue healing and combating infections.
• This study investigates the prophylactic microbicidal activity of pure (P)-PRP against key nosocomial pathogens.

Purpose of the Study:

• To evaluate the in vitro microbicidal activity of P-PRP against five major nosocomial bacterial strains.
• To compare the efficacy of P-PRP with platelet-poor plasma (PPP).
• To identify microbicidal proteins released from activated P-PRP platelets.

Main Methods:

• Assessing P-PRP and PPP microbicidal activity against varying concentrations of *Escherichia coli*, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, and *Streptococcus faecalis*.
• Incubating bacterial strains with plasma products for 1, 2, 4, and 18 hours.
• Utilizing multiplex bead-based immunoassays to quantify released microbicidal proteins.

Main Results:

• Both P-PRP and PPP demonstrated inhibitory effects on bacterial growth for up to 2 hours.
• P-PRP exhibited significantly greater inhibition than PPP, especially at lower bacterial concentrations and shorter incubation times.
• Chemokine (C-C) ligand-3, (C-C) ligand-5, and (C-X-C) ligand-1 were associated with inhibition of *P. aeruginosa*, *S. aureus*, and *S. faecalis*, while *E. coli* and *K. pneumoniae* showed less response.

Conclusions:

• P-PRP may offer early protection against bacterial contamination in surgical settings.
• The observed inhibitory activity, evident within the first hour, suggests the importance of locally supplied physiological molecules.
• These molecules may play a crucial role in the early stages of the innate immune response.